IL-17A in psoriasis and beyond

• Verfasst von: Stebut-Borschitz, Esther von [VerfasserIn]
• Verfasst von: Kaya, Ziya [VerfasserIn]
• Titel: IL-17A in psoriasis and beyond
• Titelzusatz: cardiovascular and metabolic implications
• Verf.angabe: Esther von Stebut, Wolf-Henning Boehncke, Kamran Ghoreschi, Tommaso Gori, Ziya Kaya, Diamant Thaci and Andreas Schäffler
• E-Jahr: 2020
• Jahr: 15 January 2020
• Umfang: 15 S.
• Fussnoten: Gesehen am 21.04.2020
• Titel Quelle: Enthalten in: Frontiers in immunology
• Ort Quelle: Lausanne : Frontiers Media, 2010
• Jahr Quelle: 2020
• Band/Heft Quelle: 10(2020) Artikel-Nummer 3096, 15 Seiten
• ISSN Quelle: 1664-3224
• DOI: doi:10.3389/fimmu.2019.03096
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cardiovascular
• Sach-SW: Comorbitidy
• Sach-SW: diabetes
• Sach-SW: IL-17A
• Sach-SW: Psoriasis
• K10plus-PPN: 1695259963

Abstract

Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75 % as measured by the psoriasis area and severity index (PASI) in > 80 % of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given.